Laboratory Corporation of America (LH) PT Raised to $310 at Truist

Truist Securities analyst David MacDonald raised the price target on Laboratory Corporation of America (NYSE: LH) to $310.00 (from $290.00) while maintaining a Buy rating.

The analyst commented: "Rolling Along With Strength Across Segments, FY25 Guide Upped; We remain bullish on LH following 2Q results marked by top and bottom-line beats, solid trends across segments with operating margin expansion and raised FY guidance. Diagnostic trends were ahead with better organic volumes (vs. our estimates), BLS trends were solid with FY mid single-digit CC growth expected across segments and Invitae remains on track. Mgmt provided commentary around PAMA, views recent legislative items as manageable and LaunchPad savings remain on track. Financial flexibility remains attractive, supporting execution on the pipeline and return of value to shareholders. We have raised our ‘25E – ‘26E adj. EPS; reit. Buy, PT to $310 (vs. prior $290)."

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• Jane Street Took $15 Billion Hit In July Tied To Situational Awareness - Reuters
• Berkshire adds significantly to Alphabet position, starts small position in DR Horton